Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT

Tumori

Volumn 85, Issue 1, 1999, Pages 6-11

  Del Vecchio, Michele ^a   Procopio, Giuseppe ^a   Cassata, Antonino ^a   Pozzi, Paola ^a   Busto, Giuseppina ^a   Celio, Luigi ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Fluoropyrimidines

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; RALTITREXED; TEGAFUR; UFT; URACIL;

ABDOMINAL CRAMP; ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MIXTURE; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; STOMACH CANCER; VOMITING;

EID: 0032967648     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169908500102     Document Type: Review

References (42)

1. Alonso V., Santader C., Florian J., Alonso M., Isla M.D., Escudero P., Saenz A., Tres A.: Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer. Tumori, 82: 61-64, 1996.
2. Bajetta E., Carnaghi C., Somma L., Gallo Stampino C.: A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori, 82: 450-452, 1996.
3. Bajetta E., Colleoni M., Di Bartolomeo M., Buzzoni R., Bozzetti F., Doci R., Somma L., Cappuzzo F., Gallo Stampino C., Guezzi A., Balant L.P., Zilembo N., Di Leo A.: Doxifluridine and leocovorin: An oral treatment combination in advanced colorectal cancer. J. Clin. Oncol., 13: 2613-2619, 1995.
4. Bajetta E., Di Bartolomeo M., Somma L., Del Vecchio M., Artale S., Zunino F., Bignami P., Magani E., Buzzoni R.: Doxifluridine in colorectal cancer patients resistant to fluorouracil (5-FU) containing regimens. Eur. J. Cancer, 33: 687-690, 1997.
5. Cao S., Rustum Y.M.: 5-fluorouracil prodrug ftorafur, modulated by uracil (UFT): preclinical and clinical prospectives. Tumori (suppl.), 83: S90-S93, 1997.
6. Cohen A.M., Minsky B.D., Schilsky R.L.: Cancer of the colon. In: Cancer: Principles and Practice of Oncology, De Vita V.T., Hellman S., Rosenberg S.A. (Eds.), 5th edn., pp. 1144-1197, Lippincott-Raven, Philadelphia, 1997.
7. Colleoni M., Nelli P., Manente P.: Clinical development of new fluoropyrimidines: A major improvement in colorectal cancer treatment. Tumori, 81: 303-307, 1995.
8. Daniels M., Diaz-Rubio E., Guillem V., Montero G.M., Garcia-Conde J., Estape J., Martin M., Herranz C., Ordonez A., Galan A.: Phase II trial of UFT activity in pretreated breast cancer patients. Jpn. J. Clin. Oncol., 23: 363-365, 1993.
9. Dirix L.Y., Bisset D, Van Oosterom A.T., Allman D.S., Osterwalder B., Cassidy J.: A phase I study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic solid cancer (Abst. N. 1821). Proc. Am. Soc. Clin. Oncol., 15: 496, 1996.
10. Findlay M., Van Cutsem E., Kocha W., Allman D., Laffranchi B., Griffin T., Osterwalder B., Dalley D., Pazdur R., Verweij J.: A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer (Abst. N. 798). Proc. Am. Soc. Clin. Oncol., 16: 227, 1997.
11. Folkman J.: What is the role of thymidine phosphorylase in tumor angiogenesis. J. Natl. Cancer Inst., 88: 1091-1092, 1993.
12. Friedman M.A., Ignoffo R.J.: A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat. Rev., 7: 205-213, 1980.
13. Fujita K., Munakata A.: Concentration of 5-fluorouracil in renal cells from cancer patients administered a mixture of 1 -(2-tetrahydrofuryl)-5-fluorouracil and uracil. Int. J. Clin. Pharmacol. Res., 11: 171-174, 1991.
14. Gemma A., Kudok S., Yoshimura A., Ono Y, Takenaka K., Hayashimara K., Hino M., Shibuya M., Niitani H.: Pilot trial of a combination comprising of consecutive oral administrations of UFT, and two-divided administrations of CDDP in non-small cell lung cancer. Anticancer Res., 15: 2691-2695, 1995.
15. Hashimoto T., Omura K., Ishida P., Watanabe Y.: Clinical efficacy of cis-diammine-dichloroplatin and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract. Jpn. J. Cancer Chemother., 20: 1338-1348, 1993.
16. Heidelberger C., Ansfield F.J.: Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res., 23: 1226-1243, 1963.
17. Ho D.H., Covington W.P., Pazdur R., Brown N.S., Kuritani G., Newman R.A., Rabber M.N., Krakoff I.H.: Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab. Distrib., 20: 936-940, 1992.
18. Horiuchi M., Inuyama Y., Miyake H., Head and Neck UFT Study Group: Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: a prospective randomized study (Abst. N. 918). Proc. Am. Soc. Clin. Oncol., 13: 284, 1994.
19. Hughes M., Planting A., Twelves C., Schellens J., Allman D., Osterwalder B., Kaye S., Verweij J.: A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer (Abst. N. 297). Ann. Oncol.,7 (Suppl. 1): 87, 1996.
20. Ichinose Y., Takanashi N., Yano T., Asoh H., Yokoyama H., Tayama K., Hara N., Ohta M.: A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non-small cell lung cancer. Cancer, 75: 2677-2680, 1995.
21. Jin M., Yane B., Zhane W., Wane Y.: High dose mitomycin-C containing regimens in the treatment of advanced gastric cancer. Semin. Surg. Oncol., 10: 114-116, 1994.
22. Kiman K., Suzuki S., Satomi T., Sakonji M., Nihei M., Tanaka T., Kimijima I., Abe R.: Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer. Jpn. J. Cancer Chemother., 21: 2445-2452, 1994.
23. Kojima J., Kamata T., Monna T.: Randomized trial comparing UFT and FT in the treatment of advanced hepatocellular carcinoma. Jpn. J. Cancer Chemother., 19: 637-646, 1992.
24. Kubota Y., Hosaka M., Fukushima S., Kondo I.: Prophylactic oral UFT therapy for superficial bladder cancer. Cancer, 71: 1842-1845, 1993.
25. Kunimune Y., Maruden A., Takenouchi T., Suto H., Morita K., Shimpo K., Tanabe T.: Subacute toxicity of UFT, a new anticancer agent orally administered in rats. Pharmacometrics, 20: 1027-1053, 1980.
26. Malik S.T.A., Talbot D., Clarke P.I., Osborne R., Reznek R., Wrigley P.F.M., Slevin M.L.: Phase II trial of UFT in advanced colorectal and gastric cancer. Br. J. Cancer, 62: 1023-1025, 1990.
27. Miwa M., Ura M., Nischida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda, I., Ishitsuka H.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34: 1274-1281, 1998.
28. Morimoto T., Ogawa M., Orita K., Suggimaki K., Toge T., Dohi K., Nomura Y., Monden Y., Ogawa N.: Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy, and immunotherapy of patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur. J. Cancer, 32A: 235-242, 1996.
29. Ohashi O., Yamamoto M., Ishida H., Takase S., Hasegawa K., Morita S., Kamigaki T., Saitoh Y.: Retrospective analysis of postoperative chemotherapy with UFT against pancreatic cancer. Jpn. J. Cancer Chemother., 22: 933-939, 1995.
30. Okabe H., Toko T., Saito H., Nakano K., Fujioka A., Yuasa C., Takeda S., Unemi N.: Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur 1-(2-terahydrofuryl)-5-fluorouracil with uracil, by oral leucovorin. Anticancer Res., 17: 157-164, 1997.
31. Ota K., Taguchi T., Kimura K.: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
32. Pazdur R., Lassere Y., Rhodes V., Ajani J.A., Sugarman S.M., Patt Y.Z., Jones D.V. Jr., Markovitz A.B., Abbruzzese J.L., Bready B., Levin B.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
33. Pazdur R., Rivera E., Diaz-Canton E., Lassere Y., Bready B., Win R.. Ajani J.A.: Phase I trial of UFT (uracil:tegafur) with leucovorin: 14-day schedule (Abst. n. 1568). Proc. Am. Soc. Clin. Oncol., 14:482, 1995.
34. Pazdur R., Covington W.P., Brown N.S., Lassere Y., Diaz-Canton E., Ho D.H.: Comparative steady-state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU) (Abst. n. 1498). Proc. Am. Soc. Clin. Oncol., 15:474, 1996.
35. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., Seeber S.: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Onco., 15: 389-400, 1997.
36. Sahashi M., Ono Y., Matsuura O., Ohshima S., Fukushima M.: Combination chemotherapy for advanced urothelial tract carcinoma. Cancer Chemother. Pharmacol., 30: 59-62, 1992.
37. Sakamoto S., Taga H., Uchikoshi T., Kudo H., Suzuki S., Sugiura Y., Kuwa K., Endo Y.: Synergistic effect of oral UFT in combination with cisplatin on DNA synthesis in rat hepatocarcinoma. Anticancer Res., 13:631-634, 1993.
38. Tashiro H., Nomura Y., Ohsaki A.: A double-blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn. J. Clin. Oncol., 24:212-217, 1994.
39. Terachi T., Okada Y., Takeuchi H., Yoshida O.: Long-term complete response of multiple lung metastases from renal cell carcinoma induced by combination therapy with interferon-alpha and UFT: a case report. Acta Urol. Jap., 39: 353-355, 1993.
40. Wada H., Hitomi S., Teramatsu T.: Adjuvant chemotherapy after complete resection in non small cell lung cancer. J. Clin. Oncol., 14: 1048-1054, 1996.
41. Wada T., Nishiyama K., Maeda M., Hara S., Tanaka N., Yasutomi M., Kurita T.: Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma. Anticancer Res., 15: 1581-1584, 1995.
42. Zalcberg J.R., Cunningham D., Cutsem V., Francois E., Schornagel J., Adenis A., Green M., Ivenson A., Azab M., Seymour I.: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Onco., 14: 716-721, 1996